Condition: Neoplasms · Sponsor: USWM CT, LLC
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
This description comes directly from the study's public registry record.
Investigator Study Inquiries LTFU · 866-750-8796 · Clinicaltrials2@usworldmeds.com
Always discuss trial participation with your own doctor first.
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| ADP Investigational Site | Baltimore, Maryland, United States | Recruiting |
| National Cancer Institute - Center for Cancer Research | Bethesda, Maryland, United States | Completed |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York | New York, New York, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03391778